Roivant Sciences (ROIV) said Tuesday its Kinevant Sciences unit's phase 2 Resolve-Lung trial for namilumab in chronic active pulmonary sarcoidosis failed to meet its primary and secondary endpoints.
Namilumab failed to meet the primary endpoint, showing no treatment benefit over placebo in reducing Rescue Events during the double-blind period. Secondary endpoints, including changes in lung function, corticosteroid tapering success, also did not demonstrate efficacy, it added.
Despite a safety profile consistent with earlier studies, Kinevant will discontinue namilumab's development for sarcoidosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.